Faisal Inayat*, Ahmad Azeem Khan, Arslan Afzal, Sobaan Taj, Muhammad Kashif Amin, Attiq Ur Rehman, Muhammad Hassan Naeem Goraya, Gul Nawaz, Rizwan Ishtiaq, Ali Jaan, Izzah Vasim

Inayat et al. J Clin Transl Res 2023; 9(3):4

Published online: May 12, 2023


Background and aim: Drug-induced liver injury (DILI) remains the most important etiology of acute liver failure in the United States. It often presents a diagnostic conundrum due to the lack of a specific biomarker or diagnostic modality. Liraglutide, a glucagon-like peptide-1 agonist, has recently gained clinical importance for its anti-obesity and anti-diabetic effects. While a constellation of adverse events has been reported, the published data on the safety profile remains limited. We hereby delineate a rare case of liraglutide-associated DILI. Furthermore, a systematic review of MEDLINE, Google Scholar, Scopus, and Cochrane databases was conducted on DILI following liraglutide therapy. Specific terminologies were used to identify relevant English-language articles. The latest search date was December 20, 2022. Our search identified a total of 4 case reports (level of clinical evidence: IV). We discuss the limited available data on detection, severity, causality assessment, and clinical outcomes in patients with liraglutide-induced DILI.
Relevance for Patients: DILI can rarely occur in patients undergoing liraglutide therapy. Clinicians and hepatologists can play a vital role by promptly recognizing and stopping the offending agent. Therefore, intensive pharmacovigilance is imperative for ensuring the safety of patients. Patients on liraglutide may be considered for baseline testing and periodic liver function monitoring, particularly if they have pre-existing risk factors for DILI.

DOI: http://dx.doi.org/10.18053/jctres.09.202303.004

Author affiliation

1. Allama Iqbal Medical College, Lahore, Pakistan
2. Woodhull Medical Center, Brooklyn, NY, United States of America
3. Jersey Shore University Medical Center, Neptune, NJ, United States of America
4. King Edward Medical University, Lahore, Pakistan
5. Mercy Medical Center, Baltimore, MD, United States of America
6. Saint Francis Hospital and Medical Center, Hartford, CT, United States of America
7. Wake Forest University School of Medicine, Winston Salem, NC, United States of America

*Corresponding author
Faisal Inayat
Allama Iqbal Medical College, Allama Shabbir Ahmad Usmani Road, Faisal Town, Lahore 54550, Punjab, Pakistan.
Tel: +92 321 774 3758
Fax: +92 42 9923 1443
Email: faisalinayat@hotmail.com

Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Chemistry, Utrecht University, Utrecht, the Netherlands
Department of Pathology, Erasmus Medical Center, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China


Full text PDF